TATX 115
Alternative Names: TATX-115Latest Information Update: 23 Nov 2022
At a glance
- Originator Talem Therapeutics; Twist Bioscience
- Class Anti-inflammatories; Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer; Inflammation
Most Recent Events
- 20 Sep 2022 TATX 115 is available for licensing as of 20 Sep 2022. https://talemtherapeutics.com/pipeline/
- 20 Sep 2022 Early research in Autoimmune disorders in USA (Parenteral), prior to September 2022 (Talem Therapeutics pipeline, September 2022)
- 20 Sep 2022 Early research in Cancer in USA (Parenteral), prior to September 2022 (Talem Therapeutics pipeline, September 2022)